No exemption for medical devices or IVDs (in vitro diagnostics) in EU's REACH, as Parliament and Council strike informal deal
This article was originally published in Clinica
Executive Summary
There is to be no escape for the medtech industry, and particularly the in vitro diagnostics industry, it seems, from new restrictions on the materials that they can use in manufacture and processing of their products as a result of the latest developments on the EU's REACH chemicals safety bill. The European Parliament and the Council have worked out an informal deal on the text, with little to now derail it. And medical devices and diagnostics are included within its scope.
You may also be interested in...
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.